StockIQ.techAmneal Pharmaceuticals, Inc. (AMRX) Stock Analysis
Free AI-powered analysis and research for Amneal Pharmaceuticals, Inc. stock
Sector: Healthcare
Full AMRX report
Amneal Pharmaceuticals, Inc. (AMRX) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze AMRX Now →📰 Latest Update
Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say
Tue, November 3, 2026 at 1:30 PM UTC 2 min read
Amneal Pharmaceuticals (AMRX) reported Q3 2026 revenue of $862.68 million, a 10% increase year-over-year, with an EPS of $0.26, up from $0.17 a year ago. The revenue exceeded the Zacks Consensus Estimate of $818.22 million by 5.44%, and the EPS also surpassed expectations by 8.33%. The stock has returned +0.4% over the past month, while the Zacks S&P 500 composite declined by -2.3%, earning AMRX a Zacks Rank #2 (Buy).